BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$8.15 USD
+0.19 (2.39%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $8.16 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
BCRX 8.15 +0.19(2.39%)
Will BCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCRX
Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
Other News for BCRX
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO? (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
BioCryst completes negotiations with pCPA for PrORLADEYO
Caligan Partners LP Bolsters Portfolio with Significant Stake in Liquidia Corp
BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals
Tracking Baker Brothers Portfolio - Q2 2024 Update